Analyzing generic and branded substitution patterns in the Netherlands using prescription data

BMC Health Services Research

Volumn 11, Issue , 2011, Pages

  Pechlivanoglou, Petros ^a   Van Der Veen, Willem Jan ^b   Bos, Jens H ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; GENERIC DRUG; PRESCRIPTION DRUG; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL PRACTICE; DRUG SUBSTITUTION; ECONOMICS; FACTUAL DATABASE; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; MULTIVARIATE ANALYSIS; NETHERLANDS; PHARMACIST; STATISTICS;

ANTIDEPRESSIVE AGENTS; DATABASES, FACTUAL; DRUG SUBSTITUTION; DRUGS, GENERIC; GENERAL PRACTITIONERS; HEALTH CARE COSTS; HUMANS; MULTIVARIATE ANALYSIS; NETHERLANDS; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; PROTON PUMP INHIBITORS; STATISTICS AS TOPIC;

EID: 79955143261     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-11-89     Document Type: Article

References (31)

1. European healthcare policies for controlling drug expenditure. SM Ess S Schneeweiss TD Szucs, Pharmacoeconomics 2003 21 Pt 2 89 103 12515571 (Pubitemid 36127005)
2. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. E Mossialos A Oliver, Int J Health Plann Manage 2005 20 Pt 4 291 306 16335079 (Pubitemid 41762888)
3. The Future of Medicines in Health Care: Scenario Report. Steering Committee on Future Health Scenarios, New York: Springer 1995
4. The European generic pharmaceutical market in review: 2006 and beyond. G Perry, Journal of Generic Medicines 2006 4 4 14 10.1057/palgrave.jgm.4950041 (Pubitemid 46218080)
5. A comparative analysis of generics markets in five European countries. L Garattini F Tediosi, Health policy 2000 51 Pt 3 149 162 10720685 (Pubitemid 30138050)
6. Facts and Figures 2008. AMGF Griens JL Tinke RJ van der Vaart, The Hague; The Netherlands: Foundation for Pharmaceutical Statistics 2008
7. Exploring generic drug use behavior: The role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. DA Mott RR Cline, Med Care 2002 40 Pt 8 662 74 12187180
8. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. PD Gumbs MWM Verschuren PC Souverein AK Mantel-Teeuwisse GA de Wit A de Boer OH Klungel, Br J Clin Pharmacol 2007 64 5 680 685 10.1111/j.1365-2125.2007.02958.x 17875197 (Pubitemid 47568822)
9. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. J LeLorier MS Duh PE Paradis P Lefebvre J Weiner R Manjunath O Sheehy, Neurology 2008 70 2179 86 10.1212/01.wnl.0000313154.55518.25 18505997
10. A multilevel perspective of patients and general practitioners. RE Stewart, PhD thesis University of Groningen, Public Health Department 2009
11. Age and gender. WJ van der Veen BM de Jong, Oxford textbook of primary medical care Oxford: Oxford University Press, Jones R, Britten N, Culpepper L, Gass DA, Grol R and Mant D, 2004 153 160
12. The InterAction Database: synergy of science and practice in pharmacy. H Tobi PB van den Berg LTW de Jong-van den Berg, Lect Notes in Comput Sc 2000 1933 206 211 10.1007/3-540-39949-6-25
13. Crossed Random Effect Models for Multiple Outcomes in a Study of Teratogenesis. BA Coull JP Hobert LM Ryan LB Holmes, JASA 2001 96 1194 1204 (Pubitemid 33695574)
14. Mixed-effects modelling with crossed random effects for subject and items. RH Baayen DJ Davidson DM Bates, J of Memory and Language 2008 59 Pt 4 390 412
15. Examples of mixed-effects modelling with crossed random effects and with binomial data. H Quene H van den Bergh, J Memory and Language 2008 59 4 413 425 10.1016/j.jml.2008.02.002
16. AS 181, The W Test for Normality. JP Royston, Applied Statistics 1982 31 Pt 2 176 180
17. Mixed-Effects models in S and S-PLUS. JC Pinheiro DM Bates, New York: Springer 2000
18. Analyzing Linguistic Data: A Practical Introduction to Statistics Using R. RH Baayen, Cambridge: Cambridge University Press 2008
19. Multilevel analysis: an introduction to basic and advanced multilevel modeling. TAB Snijders RJ Bosker, London: SAGE Publications Ltd 1999
20. Statistical Modeling for Biomedical Researchers. WD Dupont, Cambridge: Cambridge University Press 2009
21. A Language and Environment for Statistical Computing. R Development Core Team. R, Vienna;Austria: R Foundation for Statistical Computing 2008
22. lme4: Linear mixed-effects models using S4 classes. D Bates M Maechler B Dai, 2008 R package version 0.999375-28
23. Correlated Data Analysis. Modeling, Analytics, and Applications. PXK Song, New York: Springer 2007
24. The importance of doctors' and patients' preferences in the prescription decision. A Coscelli, J Ind Econ 2000 48 Pt 3 349 369
25. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. WH Shrank M Stedman SL Ettner,, et al. J Gen Intern Med 2007 9 1298 1304 (Pubitemid 47247307)
26. Generic substitution spells big money for retail pharmacy. ML Kirsche, Drug Store News 2005 http://findarticles.com/p/articles/mi-m3374/is-10-27/ai- n15338806 Accessed 02-03-2009
27. Do generics offer significant savings to the UK National Health Serrvice? P Kanavos, Curr Med Res Opin 2007 23 105 16 10.1185/030079907X159506 17257472 (Pubitemid 46191676)
28. The Art of Using Secondary Patents to Improve Protection. M Burdon K Sloper, International Journal of Medical Marketing 2003 3 226 229
29. Slikken. J Bouma, Amsterdam:LJ Veen 2006
30. Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands. RM Klok C Boersma I Oosterhuis ST Visser LTW De Jong-Van den Berg MJ Postma, Aliment Pharmacol Ther 2000 23 1595 1600
31. Pharmacy discounts on generic medicines in France. Is there room for further efficiency savings? P Kanavos D Taylor, Curr Med Res Opin 2007 23 2467 76 10.1185/030079907X219571 17764613 (Pubitemid 350033449)